Globeflex Capital L P acquired a new stake in Veracyte, Inc. (NASDAQ:VCYT – Get Rating) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 6,400 shares of the biotechnology company’s stock, valued at approximately $152,000.
Several other hedge funds and other institutional investors have also modified their holdings of the company. State Street Corp raised its holdings in shares of Veracyte by 45.5% during the 1st quarter. State Street Corp now owns 3,945,870 shares of the biotechnology company’s stock valued at $108,788,000 after buying an additional 1,234,244 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Veracyte by 1,717.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 807,066 shares of the biotechnology company’s stock valued at $13,397,000 after buying an additional 762,651 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Veracyte by 121.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 1,049,845 shares of the biotechnology company’s stock valued at $20,892,000 after buying an additional 575,949 shares during the period. Candriam Luxembourg S.C.A. purchased a new stake in shares of Veracyte during the 1st quarter valued at about $10,440,000. Finally, Fisher Asset Management LLC raised its holdings in shares of Veracyte by 20.0% during the 4th quarter. Fisher Asset Management LLC now owns 2,085,604 shares of the biotechnology company’s stock valued at $49,491,000 after buying an additional 348,096 shares during the period.
Wall Street Analysts Forecast Growth
Several equities research analysts recently commented on VCYT shares. StockNews.com started coverage on Veracyte in a report on Thursday, May 18th. They set a “hold” rating on the stock. Needham & Company LLC lifted their price objective on Veracyte from $33.00 to $34.00 and gave the stock a “buy” rating in a report on Thursday, February 23rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $30.20.
Veracyte Price Performance
Veracyte (NASDAQ:VCYT – Get Rating) last posted its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03. The business had revenue of $82.40 million for the quarter, compared to analyst estimates of $75.75 million. Veracyte had a negative return on equity of 2.83% and a negative net margin of 9.70%. The business’s revenue was up 21.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.20) EPS. As a group, equities research analysts expect that Veracyte, Inc. will post -0.55 EPS for the current year.
Insider Activity at Veracyte
In related news, Director Bonnie H. Anderson sold 34,000 shares of the company’s stock in a transaction on Friday, April 14th. The stock was sold at an average price of $22.04, for a total transaction of $749,360.00. Following the completion of the transaction, the director now directly owns 42,681 shares in the company, valued at approximately $940,689.24. The sale was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 2.90% of the company’s stock.
Veracyte Company Profile
Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.
- Get a free copy of the StockNews.com research report on Veracyte (VCYT)
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
Want to see what other hedge funds are holding VCYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veracyte, Inc. (NASDAQ:VCYT – Get Rating).
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.